Apr 2026 (Q1 FY27) — Jun 8, 2026
AstroNova Q1 FY27 — Aerospace strength drives 4% revenue growth and 490bps gross-margin expansion
Read the full callAstroNova (ALOT) earnings
- Apr 2026
- Apr 2026 (Q1 FY27)
- Jan 2026
AstroNova earnings: last reported Mon, 8 Jun 2026, for the quarter ended Apr 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 39.4 | +4.4% YoY | Quarterly, as filed | Quarter to Apr 2026 | Revenue from operations as filed. |
| Operating margin | 4.0 | +2.5 pts YoY | Operating profit / revenue | Quarter to Apr 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.65 | Quarterly, as filed | Quarter to Apr 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$28.99 0.00% · $0
Performance +161.9% 1Y
1Y: $11.07 on 27 Aug 2025 → $28.99. High $28.99 (25 Aug 2026), low $7.01 (8 Dec 2025).
- Previous close
- $28.99
- 52-week range
- $7.01 – $28.99
- One year
- +178.48%
Overview
- Symbol
- ALOT
- Sector
- Information Technology
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
AstroNova earnings calls (ALOT)
Financials
What the filings say
Net profit, year on year: +274% (quarter to apr 2026 against apr 2025).
| Line item | Aug 2024 | Nov 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 41 | 40 | 37 | 38 | 36 | 39 | 38 | 39 |
| Operating profit | 1 | 1 | -12 | 1 | -1 | 1 | 0 | 2 |
| Operating margin | 2.6% | 3.1% | −33.0% | 1.5% | −2.0% | 3.3% | 0.1% | 4.0% |
| Other income | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -0 | 0 | -13 | -0 | -2 | 0 | -1 | 1 |
| Tax rate | −522.0% | 12.4% | −17.7% | −24.9% | 26.8% | −51.2% | −44.0% | 23.1% |
| Net profit | -0 | 0 | -16 | -0 | -1 | 0 | -1 | 1 |
| EPS ($ per share) | -0.04 | 0.03 | — | -0.05 | -0.16 | 0.05 | — | 0.09 |
| Line item | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Reserves | 50 | 49 | 50 | 57 | 59 | 64 | 49 | 47 |
| Total liabilities | 49 | 45 | 41 | 34 | 55 | 43 | 70 | 61 |
| Fixed assets | 10 | 11 | 12 | 11 | 14 | 14 | 16 | 14 |
| Total assets | 119 | 117 | 115 | 115 | 139 | 133 | 146 | 138 |
| Line item | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5 | 3 | 16 | 1 | -3 | 12 | 5 | 12 |
| Cash from investing | -2 | -3 | -3 | -2 | -17 | -1 | -20 | -0 |
| Cash from financing | -6 | -4 | -5 | -6 | 19 | -11 | 15 | -13 |
| Net cash flow | -3 | -3 | 7 | -6 | -1 | 1 | 1 | -1 |
| Capital expenditure | -3 | -3 | -3 | -2 | -0 | -1 | -1 | -0 |
| Free cash flow | 2 | 0 | 13 | -0 | -3 | 11 | 4 | 11 |
Insider filings
50 filings between Dec 5, 2025 and Aug 26, 2026.
Open market
decisions to buy or sellNobody bought or sold ALOT on the open market in this window. The filings below are 10 awards, 14 option exercises, 13 tax withholdings and 13 dispositions to the issuer.
Compensation
not trading decisions- 10
- Award — granted as compensation
- 14
- Option exercise — converted options into shares
- 13
- Tax withheld — shares kept back by the company to cover tax
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 26, 2026 | QUAIN MITCHELL I Director | Disposition to issuer | 16,701 | $484.3K |
| Aug 26, 2026 | Carll Thomas Wayne Senior VP and GM - Aerospace | Disposition to issuer | 33,952 | $984.6K |
| Aug 26, 2026 | DeByle Thomas D. Chief Financial Officer | Disposition to issuer | 6,170 | $178.9K |
| Aug 26, 2026 | QUAIN MITCHELL I Director | Disposition to issuer | 108,910 | $3.16M |
| Aug 26, 2026 | Ittmann Jorik Chief Executive Officer | Disposition to issuer | 2,581 | $74.9K |
| Aug 26, 2026 | NEVIN DARIUS G Executive Chair | Disposition to issuer | 4,313 | $125.1K |
| Aug 26, 2026 | Natalizia Michael J Chief Technology Officer | Disposition to issuer | 47,632 | $1.38M |
| Aug 26, 2026 | MICHAS ALEXIS P Director | Disposition to issuer | 535,203 | $15.52M |
| Aug 26, 2026 | Kravetz Shawn W Director | Disposition to issuer | 9,464 | $274.5K |
| Aug 26, 2026 | WARZALA RICHARD S Director | Disposition to issuer | 75,711 | $2.20M |
| Aug 26, 2026 | Schlaeppi Yvonne Director | Disposition to issuer | 51,921 | $1.51M |
| Aug 26, 2026 | Finn Padraig Senior Vice President | Disposition to issuer | 1,685 | $48.9K |
| Aug 26, 2026 | MICHAS ALEXIS P Director | Disposition to issuer | 29,319 | $850.3K |
| Jun 10, 2026 | Natalizia Michael J Chief Technology Officer | Tax withheld | 218 | $3.5K |
| Jun 10, 2026 | Carll Thomas Wayne Vice President | Tax withheld | 193 | $3.1K |
| Jun 10, 2026 | Carll Thomas Wayne Vice President | Option exercise | 524 | $0 |
| Jun 10, 2026 | Natalizia Michael J Chief Technology Officer | Option exercise | 592 | $0 |
| Apr 17, 2026 | Carll Thomas Wayne Vice President | Option exercise | 210 | $0 |
| Apr 17, 2026 | Carll Thomas Wayne Vice President | Tax withheld | 78 | $1.0K |
| Apr 17, 2026 | Natalizia Michael J Chief Technology Officer | Option exercise | 247 | $0 |
| Apr 17, 2026 | Natalizia Michael J Chief Technology Officer | Tax withheld | 91 | $1.2K |
| Apr 14, 2026 | Carll Thomas Wayne Vice President | Tax withheld | 514 | $6.1K |
| Apr 14, 2026 | Carll Thomas Wayne Vice President | Option exercise | 1,399 | $0 |
| Apr 14, 2026 | DeByle Thomas D. Chief Financial Officer | Option exercise | 3,443 | $0 |
| Apr 14, 2026 | DeByle Thomas D. Chief Financial Officer | Tax withheld | 1,265 | $14.9K |
| Apr 14, 2026 | DeByle Thomas D. Chief Financial Officer | Option exercise | 3,395 | $0 |
| Apr 14, 2026 | DeByle Thomas D. Chief Financial Officer | Tax withheld | 1,248 | $14.7K |
| Apr 14, 2026 | Finn Padraig Senior Vice President | Option exercise | 1,085 | $0 |
| Apr 14, 2026 | Ittmann Jorik Chief Executive Officer | Tax withheld | 519 | $6.1K |
| Apr 14, 2026 | Ittmann Jorik Chief Executive Officer | Option exercise | 1,509 | $0 |
| Apr 14, 2026 | Natalizia Michael J Chief Technology Officer | Tax withheld | 494 | $5.8K |
| Apr 14, 2026 | Natalizia Michael J Chief Technology Officer | Option exercise | 1,344 | $0 |
| Apr 9, 2026 | MICHAS ALEXIS P Director | Award | 3,053 | $0 |
| Apr 9, 2026 | Kravetz Shawn W Director | Award | 2,760 | $0 |
| Apr 9, 2026 | QUAIN MITCHELL I Director | Award | 3,007 | $0 |
| Apr 9, 2026 | Schlaeppi Yvonne Director | Award | 2,873 | $0 |
| Apr 9, 2026 | WARZALA RICHARD S Director | Award | 2,827 | $0 |
| Apr 7, 2026 | Carll Thomas Wayne Vice President | Option exercise | 48 | $0 |
| Apr 7, 2026 | Carll Thomas Wayne Vice President | Tax withheld | 18 | $193 |
| Apr 7, 2026 | Natalizia Michael J Chief Technology Officer | Tax withheld | 21 | $225 |
| Apr 7, 2026 | Natalizia Michael J Chief Technology Officer | Option exercise | 56 | $0 |
| Mar 21, 2026 | Natalizia Michael J Chief Technology Officer | Tax withheld | 288 | $2.4K |
| Mar 21, 2026 | Natalizia Michael J Chief Technology Officer | Option exercise | 780 | $0 |
| Mar 21, 2026 | Carll Thomas Wayne Vice President | Tax withheld | 245 | $2.0K |
| Mar 21, 2026 | Carll Thomas Wayne Vice President | Option exercise | 664 | $0 |
| Dec 5, 2025 | WARZALA RICHARD S Director | Award | 5,018 | $0 |
| Dec 5, 2025 | Schlaeppi Yvonne Director | Award | 4,621 | $0 |
| Dec 5, 2025 | QUAIN MITCHELL I Director | Award | 4,838 | $0 |
| Dec 5, 2025 | Kravetz Shawn W Director | Award | 4,386 | $0 |
| Dec 5, 2025 | MICHAS ALEXIS P Director | Award | 4,440 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AstroNova, Inc.
Free account. Everything above stays public.
Write why you follow AstroNova, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading